Palleon Pharmaceuticals

Palleon Pharmaceuticals

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Suggest edits
Founded
2016
Raised
$148M
Follow us
Companies in the same industry
Alexa global traffic share
Twitter followers
Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2020
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2

Add info
Latest funding
$100,000,000
Venture capital (Series B) - 2020
SR One Matrix Capital Management Takeda Ventures +5
Team Size
1–10
Employees
I work here
Location
United States
Headquarters
Explore United States
$100,000,000 Venture capital (Series B)
FinSMEs

Palleon Pharmaceuticals Raises $100M in Series B Funding

Palleon Pharmaceuticals
Palleon Pharmaceuticals
$48,000,000 Venture capital (Series A)
Xconomy

Palleon Lands $48M to Develop New Type of Checkpoint Cancer Drug

Health Science Funding
Palleon Pharmaceuticals
Palleon Pharmaceuticals